Navigation Links
Barts Hospital, London enrolls first patients in ROX Medical's CONTROL-HTN resistant hypertension trial
Date:3/25/2013

SAN CLEMENTE, Calif., March 25, 2013 /PRNewswire/ -- St Bartholomew's and the London NHS Trust (Barts) have enrolled their first patients in the ROX Medical CONTROL-HTN international randomized controlled hypertension trial. The CONTROL-HTN trial is evaluating the ROX FLOW procedure - creating a small connection between artery and vein in the upper leg - for the treatment of resistant hypertension. Dr. Mel Lobo and Prof. Mark Caulfield enrolled the first patients at Barts Hospital. The first two patients randomized to the treatment group received the ROX procedure successfully performed by Dr. Ajay Kumar Jain and Prof. Anthony Mathur from the Cardiology department.

"We are very excited to be part of this trial which could lead to a novel new therapy option for resistant hypertension," commented Dr. Lobo. "We are impressed with the ease of the procedure, the need for minimal anesthesia and like the fact that it is reversible."

ROX Medical's FLOW procedure is a minimally invasive, catheter procedure to place a small coupler between the artery and vein in the upper leg. The procedure reduces peripheral vascular resistance by diverting some of the higher-pressure arterial blood to the low pressure and highly compliant venous system; essentially restoring some of the lost compliance back into the vascular system. Because the FLOW procedure does not target the sympathetic nerves or arteries of the kidneys, it may be of benefit to those patients who either cannot have or have failed to respond to renal denervation. "Because the ROX FLOW procedure is reversible and leaves all other therapy options open, we are finding more patients and physicians who see this as a first choice device therapy option for resistant hypertension," commented ROX CEO Rodney Brenneman .

"Resistant hypertension patients are a challenge for hypertension specialists and there is a need for new therapy options," added Dr. Lobo. "We are looking forward to enrolling our next patients and watching their progress over the coming months."

The ROX FLOW procedure for hypertension is not approved for use in the U.S.


'/>"/>
SOURCE ROX Medical
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Chesapeake Urologys Dr. Brad Lerner, Chief of Urology at Union Memorial Hospital, Honored with Governors Citation for Outstanding Service
2. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
3. Trovagene and Barretos Cancer Hospital, Brazil, to Evaluate Urine-Based HPV Assay as Potential Pap Smear Replacement
4. Columbia Asia Referral Hospital, Yeshwanthpur, Successfully Conducts HOLEP to Treat a 72-Year-old With Urology Disorder
5. Lilavati Hospital, Mumbai Wins Prestigious India Healthcare Awards for Best Multi Specialty Hospital of the Year and No. 1 Metro City Hospital
6. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
7. Next Generation Pharmaceutical Manufacturing Summit Pushes the Envelope of Thought-Leadership at its September Summit in London
8. Hagens Berman Sobol Shapiro LLP and Douglas & London P.C. Announce Proposed Class Action Settlement in Bayer Combination Aspirin Products Litigation
9. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
10. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
11. Emerald Logic announces collaboration with Kings College London on quantitative biomarker discovery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Israel , January 17, 2017 Management ... TyrNovo, Ltd.   KIT-302 Development On Track For ... FDA in Q1 2017   ... Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV ; ... update call on Monday, January 23 rd at 8:30am Eastern Time to ...
(Date:1/17/2017)... 17, 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ... enrolled in a Phase 3 clinical trial comparing the ... (BSC) in the prevention of hepatic veno-occlusive disease (VOD) ... transplant (HSCT) who are at high risk or at ... trial will be conducted across approximately 100 medical centers ...
(Date:1/17/2017)... Calif. , Jan. 17, 2017  Edwards Lifesciences ... in patient-focused innovations for structural heart disease and critical ... the quarter ended December 31, 2016 after the market ... a conference call at 5:00 p.m. ET that day ... the conference call, dial (877) 407-8037 or (201) 689-8037.  ...
Breaking Medicine Technology:
(Date:1/18/2017)... ... January 18, 2017 , ... Rollerblade®, the worldwide ... (ABT), an innovative braking system that allows skaters of all levels to stop ... the biggest concerns of beginner and intermediate skaters – learning how to brake ...
(Date:1/18/2017)... ... 18, 2017 , ... Floundering on New Year’s resolutions? Need an excuse to ... a reset. The U.S. Apple Association agrees and recommends starting each day with ... contribute to heart disease. , The U.S. Apple Association – which represents apple growers ...
(Date:1/17/2017)... ... ... Anesthesia Progress – Everyone wants less pain during dental surgery, but ... patient. Dentists have several general anesthesia alternatives and finding the right option can result ... College in Tokyo, Japan wanted to find out which anesthetic was the better choice ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... of difference. Eden Activewear is a stand-out company for several differences from other ... and only manufacture on demand, this is called 'Agile' manufacturing - http://www.leanproduction.com/agile-manufacturing.html ...
(Date:1/17/2017)... ... January 17, 2017 , ... Today, to help those who ... powerfully uplifting interview with medical expert and prolific author, Dr. Bernie Siegel. ... tough times, Dr. Bernie Siegel energizes listeners to live life with intrigue, magic ...
Breaking Medicine News(10 mins):